Related Experiment Video
Updated: May 21, 2026
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Host CD73 impairs anti-tumor immunity
1MediCity Research Laboratory; University of Turku; Turku, Finland ; Department of Medical Biochemistry and Genetics; University of Turku; Turku, Finland ; National Institute of Health and Welfare; Tykistökatu; Turku, Finland.
Abstract:
The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor growth and tumor infiltration by Tregs and type 2 immunosuppressive macrophages is reduced. Pharmacological inhibition of CD73 in wild-type mice has similar tumor-suppressing effects. Host CD73 on leukocytes and endothelial cells is thus detrimental for the anti-tumor immunity.
Insights
CD73 enzyme activity creates immune-suppressing adenosine, hindering anti-tumor responses. Inhibiting CD73 in hosts reduces tumor growth and immune suppression, boosting anti-cancer immunity.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- CD73 is an enzyme crucial in purinergic signaling.
- Its activity generates adenosine, a molecule known to suppress immune responses.
- Tumor microenvironments often exhibit elevated CD73 expression, contributing to immune evasion.
Purpose of the Study:
- To investigate the role of CD73 in anti-tumor immunity.
- To determine the effects of CD73 deficiency and pharmacological inhibition on tumor progression.
- To elucidate the impact of host CD73 expression on immune cell infiltration in tumors.
Main Methods:
- Comparative analysis of tumor growth in CD73-deficient and wild-type mice.
- Assessment of tumor-infiltrating immune cells, including regulatory T cells (Tregs) and M2 macrophages.
- Pharmacological inhibition of CD73 activity in wild-type mice models.
- Evaluation of anti-tumor immune responses.
Main Results:
- CD73-deficient hosts exhibited reduced tumor growth.
- Tumor infiltration by Tregs and type 2 immunosuppressive macrophages was decreased in CD73-deficient hosts.
- Pharmacological inhibition of CD73 in wild-type mice mirrored these tumor-suppressing effects.
- Host CD73 expression on leukocytes and endothelial cells was found to be detrimental to anti-tumor immunity.
Conclusions:
- Host CD73 enzymatic activity promotes tumor growth by producing immune-suppressive adenosine.
- Targeting CD73, either genetically or pharmacologically, can enhance anti-tumor immunity.
- CD73 represents a potential therapeutic target for cancer immunotherapy.
